Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. NVDA
2. SPY
3. META
4. USO
5. LGND
6. ONON
7. VKTX
8. DCOY
9. GS
10. PSKY

Go back to Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis

Vitae Pharmaceuticals (VTAE) PT Raised to $23 at Wedbush

March 18, 2016 6:42 AM EDT

Wedbush analyst Liana Moussatos reiterated an Outperform rating and raised her price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $23.00 (from $20.00) after proof-of-concept for RAR-Related Orphan Receptor -t ( ROR t) inhibition was achieved, in their view.

Moussatos commented: "The randomized, double blind multiple ascending dose (MAD) Part II trial tested once-daily, orally-dosed... More

JMP Securities Upgrades Vitae Pharmaceuticals (VTAE) to Market Outperform

March 17, 2016 9:33 AM EDT

JMP Securities upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Market Perform to Market Outperform.

For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.

Shares of Vitae Pharmaceuticals closed at $4.11 yesterday.

... More

Stifel Upgrades Vitae Pharmaceuticals (VTAE) to Buy, $15 PT

March 17, 2016 6:27 AM EDT

Stifel upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Hold to Buy with a price target of $15.00, saying 43742 Data shows drug potential is significant, and toxic signal seems manageable.

Analyst Thomas Shrader commented, "Vitae release its eagerly awaited topline data for VTP-43742 and the drug is clearly active.... More